During the past decade, Sarah Cannon Research Institute at HealthONE conducted 57 clinical trials. In the 10-year time frame, 57 clinical trials started and 4 clinical trials were completed, i.e. on average, 7% percent of trials that started reached the finish line to date. In the past 5 years, 40 clinical trials started and 4 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sarah Cannon Research Institute at HealthONE" #1 sponsor was "Amgen" with 4 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Prelude Therapeutics" with 3 trials sponsored, "Regeneron Pharmaceuticals" with 3 trials sponsored and "Turning Point Therapeutics, Inc." with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sarah Cannon Research Institute at HealthONE" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Boehringer Ingelheim" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Sarah Cannon Research Institute at HealthONE" are "Advanced Solid Tumor" (13 trials), "Advanced Solid Tumors" (6 trials), "Solid Tumor" (6 trials), "Breast Cancer" (5 trials) and "Ovarian Cancer" (5 trials). Many other conditions were trialed in "Sarah Cannon Research Institute at HealthONE" in a lesser frequency.

Most popular intervention types in "Sarah Cannon Research Institute at HealthONE" are "Drug" (52 trials), "Biological" (8 trials), "Other" (1 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (7 trials), "Nivolumab" (3 trials), "AMG 404" (2 trials), "Cemiplimab" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Sarah Cannon Research Institute at HealthONE" are 56 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Sarah Cannon Research Institute at HealthONE". undefined are not yet recruiting, 32 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Sarah Cannon Research Institute at HealthONE, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Sarah Cannon Research Institute at HealthONE, 53 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".